The company remains pre-revenue with no operational leverage, sustaining quarterly operating losses that peaked at $6.0 million in 2025Q4.
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 768 | 0 | 3.31K | 4.13K | 11.76K | 13.07K | 11.1K | 1.96K | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | -768 | 0 | -3.31K | -4.13K | -11.76K | -13.07K | -11.1K | -1.96K | 0 | 0 |
| Gross Margin % | - | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | 100% | 20.03% | 64.83% | 10.05% | -17.79% | -467.57% | - | - | - |
| Operating Expenses | 16.62M | 15.99M | 14.9M | 18.86M | 14.92M | 14.47M | 9.44M | 3.83M | 881.79K | 215.1K |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 6.55M | 6.21M | 5.61M | 4.77M | 5.62M | 4.67M | 4.38M | 1.98M | 860.52K | 182.47K |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Research & Development | 10.07M | 9.77M | 9.29M | 14.1M | 9.3M | 9.81M | 5.06M | 1.85M | 21.27K | 32.64K |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | -4.13K | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -16.62M | -15.99M | -14.9M | -18.87M | -14.93M | -14.49M | -9.45M | -3.83M | -881.79K | -516.25K |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | - | -7.28% | 21.01% | -26.33% | -3.09% | -53.22% | -146.66% | -334.68% | -70.81% | - |
| EBITDA | -16.62M | -15.98M | -14.9M | -18.86M | -14.92M | -14.47M | -9.44M | -3.83M | 0 | 0 |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | -5.92% | -7.28% | 21.01% | -26.4% | -3.1% | -53.26% | -146.5% | - | - | - |
| D&A (Non-Cash Add-back) | 4.69K | 3.92K | 3.31K | 4.13K | 11.76K | 13.07K | 11.1K | 1.96K | 881.79K | 516.25K |
| EBIT | -16.52M | -15.84M | -14.84M | -18.87M | -15.27M | -14.49M | -9.45M | -3.83M | -7.35M | -516.25K |
| Net Interest Income | 140.37K | 138.56K | 44.14K | 13.88K | -7.03K | -9.28K | -3.26K | -44.23K | -46.7K | -4.26K |
| Interest Income | 155.51K | 153.78K | 60.26K | 27.69K | 7 | 9 | 3 | 44 | 0 | 0 |
| Interest Expense | 15.13K | 15.23K | 16.12K | 13.8K | 7.03K | 9.29K | 3.26K | 44.23K | 46.7K | 4.26K |
| Other Income/Expense | 137.81K | 136K | 44.14K | 13.88K | -341.17K | -9.29K | -3.26K | -44.23K | -6.51M | -4.26K |
| Pretax Income | -16.49M | -15.85M | -14.86M | -18.85M | -15.27M | -14.5M | -9.46M | -3.88M | -7.39M | -219.36K |
| Pretax Margin % | - | - | - | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -16.49M | -15.85M | -14.86M | -18.85M | -15.27M | -14.5M | -9.46M | -3.88M | -7.39M | -526.47K |
| Net Margin % | - | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | -5.58% | -6.68% | 21.18% | -23.42% | -5.37% | -53.26% | -143.93% | 47.55% | -1304.05% | - |
| Net Income (Continuing) | -16.49M | -15.85M | -14.86M | -18.85M | -15.27M | -14.5M | -9.46M | -3.88M | -7.39M | -219.36K |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -24.38 | -35.75 | -466.44 | -150114.00 | -336499.00 | -495027.00 | -512208.00 | -212121.00 | -404415.00 | -11997.00 |
| EPS Growth % | 99.3% | 92.34% | 99.69% | 55.39% | 32.02% | 3.35% | -141.47% | 47.55% | -3270.97% | - |
| EPS (Basic) | - | -35.75 | -466.44 | -150114.00 | -336499.00 | -495027.00 | -512208.00 | -212121.00 | -404415.00 | -11997.00 |
| Diluted Shares Outstanding | 676.17K | 443.37K | 31.85K | 126 | 45 | 29 | 18 | 18 | 18 | 18 |
| Basic Shares Outstanding | 676.17K | 443.37K | 31.85K | 126 | 45 | 29 | 18 | 18 | 18 | 18 |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
Single-asset clinical failure risk
As reported in financial statements, CNSP's quarterly R&D expenditures have fluctuated between $1.1 million and $4.3 million, reflecting the inherent volatility of clinical trial milestones and patient enrollment cycles that define the company's current operational footprint as a pre-revenue, single-asset biotechnology entity.
The cost structure is almost entirely composed of discretionary R&D spending, which lacks the predictability of commercial-stage operations. Investors should monitor the efficiency of these outlays, as the lack of revenue means every dollar spent directly depletes the limited $7.2 million cash reserve.
Based on the provided income statement data, EPS volatility remains extreme, with figures ranging from -7.30 to -28,623.00, suggesting that historical share count adjustments and periodic stock-based compensation have significantly distorted the per-share loss metrics over the last ten quarters.
The erratic EPS trajectory appears to be a function of capital structure management rather than underlying operational performance. Analysts should focus on absolute net loss figures to gauge the true rate of capital consumption, as per-share metrics are currently unreliable indicators of fundamental health.
According to recent SEC filings, CNSP continues to operate without any revenue generation, resulting in a total absence of operating leverage as the company sustains quarterly operating losses that have reached as high as $6.0 million in recent periods.
The lack of a commercial product means that SG&A and R&D expenses scale independently of any top-line growth. This creates a binary risk profile where the company's survival is entirely decoupled from operational efficiency and tethered strictly to the success of the Berubicin clinical program.
Financial data indicates that with only $7.2 million in cash and quarterly operating losses often exceeding $3 million, the company faces a significant financing overhang that may necessitate further dilutive equity raises to sustain its current clinical trial trajectory.
Short-term observers may focus on the potential for clinical breakthroughs, but the fundamental reality is that the current cash runway appears insufficient for long-term development. This suggests that even positive clinical news may be met with immediate share dilution, capping the upside for existing shareholders.
Quick answers to the most common questions about buying CNSP stock.
For fiscal year 2025, CNS Pharmaceuticals, Inc. (CNSP) reported total revenue of $0.0M.
CNS Pharmaceuticals, Inc. (CNSP) reported a net loss of $15.9M for the fiscal year ending 2025.